Search

Your search keyword '"Vizza, D."' showing total 108 results
Start Over Author "Vizza, D."
108 results on '"Vizza, D."'

6. Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy

Author

Rosenkranz, S, primary, Benza, R L, additional, Ghofrani, H A, additional, Gruenig, E, additional, Hoeper, M M, additional, Peacock, A, additional, Simonneau, G, additional, Vizza, D, additional, Meier, C, additional, Vogtlaender, K, additional, and Vonk-Noordegraaf, A, additional

Published
2021
Full Text
View/download PDF

14. Olive leaf extract counteracts cell proliferation and cyst growth in anin vitromodel of autosomal dominant polycystic kidney disease

Author

Toteda, G., primary, Vizza, D., additional, Lupinacci, S., additional, Perri, A., additional, Scalise, M. F., additional, Indiveri, C., additional, Puoci, F., additional, Parisi, O. I., additional, Lofaro, D., additional, La Russa, A., additional, Gigliotti, P., additional, Leone, F., additional, Pochini, L., additional, and Bonofiglio, R., additional

Published
2018
Full Text
View/download PDF

15. Epigallocatechin gallate inhibits growthand epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines

Author

De Amicis F, Perri A, Vizza D, Russo A, Panno ML, Bonofiglio D, Giordano C, Mauro L, Aquila S, Andò S., TRAMONTANO, DONATELLA, De Amicis, F, Perri, A, Vizza, D, Russo, A, Panno, Ml, Bonofiglio, D, Giordano, C, Mauro, L, Aquila, S, Tramontano, Donatella, and Andò, S.

Abstract

Well-differentiated papillary and follicular thyroid carcinoma are the most frequent types of thyroid cancer and the prognosis is generally favorable however, a number of patients develops recurrences. Epigallocatechin-3-gallate (EGCG), a major catechin in green tea, was shown to possess remarkable therapeutic potential against various types of human cancers, although data on thyroid cancer cells are still lacking. The aim of this study was to investigate the effect of EGCG on the proliferation and motility of human thyroid papillary (FB-2) and follicular (WRO) carcinoma cell lines. Our results demonstrate that EGCG (10, 40, 60 μM) treatment inhibited the growth of FB-2 and WRO cells in a dose-dependent manner. These changes were associated with reduced cyclin D1, increased p21 and p53 expression. Furthermore, EGCG suppressed phosphorylation of AKT and ERK1/2. In addition EGCG treatment results in reduction of cell motility and migration. Changes in motility and migration in FB-2 were associated with modulation in the expression of several proteins involved in cell adhesion and reorganization of actin cytoskeleton. After 24 h EGCG caused an increase of the E-cadherin expression and a concomitant decrease of SNAIL, ZEB and the basic helix-loop-helix transcription factor TWIST. Besides expression of Vimentin, N-cadherin and α5-integrin was down-regulated. These data well correlate with a reduction of MMP9 activity as evidenced by gelatin zymography. Our findings support the inhibitory role of EGCG on thyroid cancer cell proliferation and motility with concomitant loss of epithelial-to-mesenchymal cell transition markers.

Published
2013

19. TRANSPLANTATION CLINICAL 1

Author

Schachtner, T., primary, Reinke, P., additional, Dorje, C., additional, Mjoen, G., additional, Midtvedt, K., additional, Strom, E. H., additional, Oyen, O., additional, Jenssen, T., additional, Reisaeter, A. V., additional, Smedbraaten, Y. V., additional, Sagedal, S., additional, Fagerland, M. W., additional, Hartmann, A., additional, Thiel, S., additional, Zulkarnaev, A., additional, Vatazin, A., additional, Vincenti, F., additional, Harel, E., additional, Kantor, A., additional, Thurison, T., additional, Hoyer-Hansen, G., additional, Craik, C., additional, Kute, V. B., additional, Shah, P. S., additional, Vanikar, A. V., additional, Modi, P. R., additional, Shah, P. R., additional, Gumber, M. R., additional, Patel, H. V., additional, Engineer, D. P., additional, Shah, V. R., additional, Rizvi, J., additional, Trivedi, H. L., additional, Malheiro, J., additional, Dias, L., additional, Martins, L. S., additional, Fonseca, I., additional, Pedroso, S., additional, Almeida, M., additional, Castro-Henriques, A., additional, Cabrita, A., additional, Costa, C., additional, Ritta, M., additional, Sinesi, F., additional, Sidoti, F., additional, Mantovani, S., additional, Di Nauta, A., additional, Messina, M., additional, Cavallo, R., additional, Verflova, A., additional, Svobodova, E., additional, Slatinska, J., additional, Slavcev, A., additional, Pokorna, E., additional, Viklicky, O., additional, Yagan, J., additional, Chandraker, A., additional, Diena, D., additional, Tognarelli, G., additional, Ranghino, A., additional, Bussolino, S., additional, Fop, F., additional, Segoloni, G. P., additional, Biancone, L., additional, Leone, F., additional, Mauro, M. V., additional, Gigliotti, P., additional, Lofaro, D., additional, Greco, F., additional, Perugini, D., additional, Papalia, T., additional, Perri, A., additional, Vizza, D., additional, Giraldi, C., additional, Bonofilgio, R., additional, Luis-Lima, S., additional, Marrero, D., additional, Gonzalez-Rinne, A., additional, Torres, A., additional, Salido, E., additional, Jimenez-Sosa, A., additional, Aldea-Perona, A., additional, Gonzalez-Posada, J. M., additional, Perez-Tamajon, L., additional, Rodriguez-Hernandez, A., additional, Negrin-Mena, N., additional, Porrini, E., additional, Pihlstrom, H., additional, Dahle, D. O., additional, Holdaas, H., additional, Von Der Lippe, N., additional, Waldum, B., additional, Brekke, F., additional, Amro, A., additional, Os, I., additional, Klin, P., additional, Sanabria, H., additional, Bridoux, P., additional, De Francesco, J., additional, Fortunato, R. M., additional, Raffaele, P., additional, Kong, J., additional, Son, S. H., additional, Kwon, H. Y., additional, Whang, E. J., additional, Choi, W. Y., additional, Yoon, C. S., additional, Thanaraj, V., additional, Theakstone, A., additional, Stopper, K., additional, Ferraro, A., additional, Bhattacharjya, S., additional, Devonald, M., additional, Williams, A., additional, Mella, A., additional, Gallo, E., additional, Di Vico, M. C., additional, Pagani, F., additional, Gai, M., additional, Cho, H. J., additional, Nho, K. W., additional, Park, S.-K., additional, Kim, S. B., additional, Yoshida, K., additional, Ishii, D., additional, Ohyama, T., additional, Kohguchi, D., additional, Takeuchi, Y., additional, Varga, A., additional, Sandor, B., additional, Kalmar-Nagy, K., additional, Toth, A., additional, Toth, K., additional, Szakaly, P., additional, Kildushevsky, A., additional, Fedulkina, V., additional, Kantaria, R., additional, Staeck, O., additional, Halleck, F., additional, Rissling, O., additional, Naik, M., additional, Neumayer, H.-H., additional, Budde, K., additional, Khadzhynov, D., additional, Bhadauria, D., additional, Kaul, A., additional, Prasad, N., additional, Sharma, R. K., additional, Sezer, S., additional, Bal, Z., additional, Erkmen Uyar, M., additional, Guliyev, O., additional, Erdemir, B., additional, Colak, T., additional, Ozdemir, N., additional, Haberal, M., additional, Caliskan, Y., additional, Yazici, H., additional, Artan, A. S., additional, Oto, O. A., additional, Aysuna, N., additional, Bozfakioglu, S., additional, Turkmen, A., additional, Yildiz, A., additional, Sever, M. S., additional, Yagisawa, T., additional, Nukui, A., additional, Kimura, T., additional, Nannmoku, K., additional, Kurosawa, A., additional, Sakuma, Y., additional, Miki, A., additional, Damiano, F., additional, Ligabue, G., additional, De Biasi, S., additional, Granito, M., additional, Cossarizza, A., additional, Cappelli, G., additional, Henriques, A. C., additional, Davide, J., additional, Von During, M. E., additional, Jenssen, T. G., additional, Bollerslev, J., additional, Godang, K., additional, Asberg, A., additional, Bachelet, T., additional, Martinez, C., additional, Bello, A., additional, Kejji, S., additional, Couzi, L., additional, Guidicelli, G., additional, Lepreux, S., additional, Visentin, J., additional, Congy-Jolivet, N., additional, Rostaing, L., additional, Taupin, J.-L., additional, Kamar, N., additional, Merville, P., additional, Ozdemir, H., additional, Yildirim, S., additional, Tutal, E., additional, Sayin, B., additional, Ozdemir Acar, N., additional, Banasik, M., additional, Boratynska, M., additional, Koscielska-Kasprzak, K., additional, Kaminska, D., additional, Bartoszek, D., additional, Mazanowska, O., additional, Krajewska, M., additional, Zmonarski, S., additional, Chudoba, P., additional, Dawiskiba, T., additional, Protasiewicz, M., additional, Halon, A., additional, Sas, A., additional, Kaminska, M., additional, Klinger, M., additional, Stefanovic, N., additional, Cvetkovic, T., additional, Velickovic - Radovanovic, R., additional, Jevtovic - Stoimenov, T., additional, Vlahovic, P., additional, Rungta, R., additional, Das, P., additional, Ray, D. S., additional, Gupta, S., additional, Kolonko, A., additional, Szotowska, M., additional, Kuczera, P., additional, Chudek, J., additional, Wiecek, A., additional, Sikora-Grabka, E., additional, Adamczak, M., additional, Madej, P., additional, Amanova, A., additional, Kendi Celebi, Z., additional, Bakar, F., additional, Caglayan, M. G., additional, Keven, K., additional, Massimetti, C., additional, Imperato, G., additional, Zampi, G., additional, De Vincenzi, A., additional, Fabbri, G. D. D., additional, Brescia, F., additional, Feriozzi, S., additional, Filipov, J. J., additional, Zlatkov, B. K., additional, Dimitrov, E. P., additional, Svinarov, D. A., additional, Poesen, R., additional, De Vusser, K., additional, Evenepoel, P., additional, Kuypers, D., additional, Naesens, M., additional, Meijers, B., additional, Kocak, H., additional, Yilmaz, V. T., additional, Yilmaz, F., additional, Uslu, H. B., additional, Aliosmanoglu, I., additional, Ermis, H., additional, Dinckan, A., additional, Cetinkaya, R., additional, Ersoy, F. F., additional, Suleymanlar, G., additional, Oliveira, J.-C., additional, Santos, J., additional, Lobato, L., additional, Mendonca, D., additional, Watarai, Y., additional, Yamamoto, T., additional, Tsujita, M., additional, Hiramitsu, T., additional, Goto, N., additional, Narumi, S., additional, Kobayashi, T., additional, Line, P.-D., additional, Housawi, A., additional, House, A., additional, Ng, C., additional, Denesyk, K., additional, Rehman, F., additional, Moist, L., additional, Musetti, C., additional, Battista, M., additional, Izzo, C., additional, Guglielmetti, G., additional, Airoldi, A., additional, Stratta, P., additional, Cena, T., additional, Quaglia, M., additional, Fenoglio, R., additional, Cagna, D., additional, Amoroso, A., additional, Palmisano, A., additional, Degli Antoni, A. M., additional, Vaglio, A., additional, Piotti, G., additional, Cremaschi, E., additional, Buzio, C., additional, Maggiore, U., additional, Lee, M.-C., additional, Hsu, B.-G., additional, Zalamea Jarrin, F., additional, Sanchez Sobrino, B., additional, Lafuente Covarrubias, O., additional, Karsten Alvarez, S., additional, Dominguez Apinaniz, P., additional, Llopez Carratala, R., additional, Portoles Perez, J., additional, Yildirim, T., additional, Yilmaz, R., additional, Turkmen, E., additional, Altindal, M., additional, Arici, M., additional, Altun, B., additional, Erdem, Y., additional, Dounousi, E., additional, Mitsis, M., additional, Naka, K., additional, Pappas, H., additional, Lakkas, L., additional, Harisis, H., additional, Pappas, K., additional, Koutlas, V., additional, Tzalavra, I., additional, Spanos, G., additional, Michalis, L., additional, Siamopoulos, K., additional, Iwabuchi, T., additional, Nanmoku, K., additional, Yasunaru, S., additional, Yoshikawa, M., additional, Kitamura, K., additional, Fuji, H., additional, Fujisawa, M., additional, Nishi, S., additional, Carta, P., additional, Zanazzi, M., additional, Buti, E., additional, Larti, A., additional, Caroti, L., additional, Di Maria, L., additional, Minetti, E. E., additional, Shi, Y., additional, Luo, L., additional, Cai, B., additional, Wang, T., additional, Zou, Y., additional, Wang, L., additional, Kim, Y., additional, Kim, H. S., additional, Choi, B. S., additional, Park, C. W., additional, Yang, C. W., additional, Kim, Y.-S., additional, Chung, B. H., additional, Baek, C. H., additional, Kim, M., additional, Kim, J.-S., additional, Yang, W. S., additional, Han, D. J., additional, Mikolasevic, I., additional, Racki, S., additional, Lukenda, V., additional, Persic, M. P., additional, Colic, M., additional, Devcic, B., additional, Orlic, L., additional, Gurlek Demirci, B., additional, Say N, C. B., additional, Ozdemir Acar, F. N., additional, Vali, S., additional, Ismal, K., additional, Sahay, M., additional, Civiletti, F., additional, Cantaluppi, V., additional, Medica, D., additional, Mazzeo, A. T., additional, Assenzio, B., additional, Mastromauro, I., additional, Deambrosis, I., additional, Giaretta, F., additional, Fanelli, V., additional, Mascia, L., additional, Gkirdis, I., additional, Bechlioulis, A., additional, Evangelou, D., additional, Zarzoulas, F., additional, Kotsia, A., additional, Balafa, O., additional, Tzeltzes, G., additional, Nakas, G., additional, Kalaitzidis, R., additional, Katsouras, C., additional, Uyanik, S., additional, Toprak, S. K., additional, Ilhan, O., additional, Ekmen Uyar, M., additional, Hernandez Vargas, H., additional, Artamendi Larranaga, M., additional, Ramalle Gomara, E., additional, Gil Catalinas, F., additional, Bello Ovalle, A., additional, Pimentel Guzman, G., additional, Coloma Lopez, A., additional, Sierra Carpio, M., additional, Gil Paraiso, A., additional, Dall Anesse, C., additional, Beired Val, I., additional, Huarte Loza, E., additional, Choy, B. Y., additional, Kwan, L., additional, Mok, M., additional, Chan, T. M., additional, Yamakawa, T., additional, Kobayashi, A., additional, Yamamoto, I., additional, Mafune, A., additional, Nakada, Y., additional, Tannno, Y., additional, Tsuboi, N., additional, Yamamoto, H., additional, Yokoyama, K., additional, Ohkido, I., additional, Yokoo, T., additional, Luque, Y., additional, Anglicheau, D., additional, Rabant, M., additional, Clement, R., additional, Kreis, H., additional, Sartorius, A., additional, Noel, L.-H., additional, Timsit, M.-O., additional, Legendre, C., additional, Rancic, N., additional, Vavic, N., additional, Dragojevic-Simic, V., additional, Katic, J., additional, Jacimovic, N., additional, Kovacevic, A., additional, Mikov, M., additional, Veldhuijzen, N. M. H., additional, Rookmaaker, M. B., additional, Van Zuilen, A. D., additional, Nquyen, T. Q., additional, Boer, W. H., additional, Sahtout, W., additional, Ghezaiel, H., additional, Azzebi, A., additional, Ben Abdelkrim, S., additional, Guedri, Y., additional, Mrabet, S., additional, Nouira, S., additional, Ferdaws, S., additional, Amor, S., additional, Belarbia, A., additional, Zellama, D., additional, Mokni, M., additional, Achour, A., additional, Parikova, A., additional, Hanzal, V., additional, Fronek, J., additional, Orandi, B. J., additional, James, N. T., additional, Montgomery, R. A., additional, Desai, N. M., additional, Segev, D. L., additional, Fontana, F., additional, Ballestri, M., additional, and Magistroni, R., additional

Published
2014
Full Text
View/download PDF

20. PATHOLOGY: IMMUNE AND INFLAMMATORY MECHANISMS

Author

Kozakowski, N., primary, Herkner, H., additional, Bohmig, G. A., additional, Kikic, Z., additional, Cooper, D. J., additional, Eller, K., additional, Kirsch, A. H., additional, Lane, P. J., additional, Neirynck, N., additional, Glorieux, G., additional, Schepers, E., additional, Dhondt, A., additional, Vanholder, R., additional, Corradetti, V., additional, Milanesi, S., additional, Rocca, C., additional, Avanzini, M. A., additional, Pattonieri, E. F., additional, Bosio, F., additional, Cannone, M., additional, Maggi, N., additional, Gregorini, M., additional, Esposito, P., additional, Rampino, T., additional, Dal Canton, A., additional, Roelofs, J. J., additional, Redecha, P., additional, Salmon, J. E., additional, Rho, E., additional, Artinger, K., additional, Schaubettl, C., additional, Aringer, I., additional, Rosenkranz, A. R., additional, Eller, P., additional, Perri, A., additional, Vizza, D., additional, Toteda, G., additional, Lupinacci, S., additional, Lofaro, D., additional, Leone, F., additional, Gigliotti, P., additional, La Russa, A., additional, Papalia, T., additional, Bonofilgio, R., additional, and Schabhuttl, C., additional

Published
2014
Full Text
View/download PDF

21. TRANSPLANTATION BASIC SCIENCE, ALLOGENIC AND XENOGENIC TOLERANCE

Author

Berthelot, L., primary, Robert, T., additional, Tabary, T., additional, Vuiblet, V., additional, Drame, M., additional, Toupance, O., additional, Rieu, P., additional, Monteiro, R. C., additional, Toure, F., additional, Ferrario, S., additional, Cantaluppi, V., additional, De Lena, M., additional, Dellepiane, S., additional, Beltramo, S., additional, Rossetti, M., additional, Manzione, A. M., additional, Messina, M., additional, Gai, M., additional, Dolla, C., additional, Biancone, L., additional, Camussi, G., additional, Pontrelli, P., additional, Oranger, A. R., additional, Accetturo, M., additional, Rascio, F., additional, Gigante, M., additional, Castellano, G., additional, Schena, A., additional, Fiorentino, M., additional, Zito, A., additional, Zaza, G., additional, Stallone, G., additional, Gesualdo, L., additional, Grandaliano, G., additional, Pattonieri, E. F., additional, Gregorini, M., additional, Corradetti, V., additional, Rocca, C., additional, Milanesi, S., additional, Peloso, A., additional, Ferrario, J., additional, Cannone, M., additional, Bosio, F., additional, Maggi, N., additional, Avanzini, M. A., additional, Minutillo, P., additional, Paulli, M., additional, Maestri, M., additional, Rampino, T., additional, Dal Canton, A., additional, Wu, K. S. T., additional, Coxall, O., additional, Luque, Y., additional, Candon, S., additional, Rabant, M., additional, Noel, L.-H., additional, Thervet, E., additional, Chatenoud, L., additional, Snanoudj, R., additional, Anglicheau, D., additional, Legendre, C., additional, Zuber, J., additional, Hruba, P., additional, Brabcova, I., additional, Krepsova, E., additional, Slatinska, J., additional, Sekerkova, A., additional, Striz, I., additional, Zachoval, R., additional, Viklicky, O., additional, Scholbach, T. M., additional, Wang, H.-K., additional, Loong, C.-C., additional, Yang, A.-H., additional, Wu, T.-H., additional, Guberina, H., additional, Rebmann, V., additional, Dziallas, P., additional, Dolff, S., additional, Wohlschlaeger, J., additional, Heinemann, F. M., additional, Witzke, O., additional, Zoet, Y. M., additional, Claas, F. H. J., additional, Horn, P. A., additional, Kribben, A., additional, Doxiadis, I. I. N., additional, Prasad, N., additional, Yadav, B., additional, Agarwal, V., additional, Jaiswal, A., additional, Rai, M., additional, Hope, C. M., additional, Coates, P. T., additional, Heeger, P. S., additional, Carroll, R., additional, Masola, V., additional, Secchi, M. F., additional, Onisto, M., additional, Gambaro, G., additional, Lupo, A., additional, Matsuyama, M., additional, Kobayashi, T., additional, Yoneda, Y., additional, Chargui, J., additional, Touraine, J. L., additional, Yoshimura, R., additional, Vizza, D., additional, Perri, A., additional, Lupinacci, S., additional, Toteda, G., additional, Lofaro, D., additional, Leone, F., additional, Gigliotti, P., additional, La Russa, A., additional, Papalia, T., additional, Bonofilgio, R., additional, Sentis Fuster, A., additional, Kers, J., additional, Yapici, U., additional, Claessen, N., additional, Bemelman, F. J., additional, Ten Berge, I. J. M., additional, Florquin, S., additional, Glotz, D., additional, Rostaing, L., additional, Squifflet, J.-P., additional, Merville, P., additional, Belmokhtar, C., additional, Le Ny, G., additional, Lebranchu, Y., additional, Papazova, D. A., additional, Friederich-Persson, M., additional, Koeners, M. P., additional, Joles, J. A., additional, Verhaar, M. C., additional, Trivedi, H. L., additional, Vanikar, A. V., additional, Dave, S. D., additional, Suarez Alvarez, B., additional, Garcia Melendreras, S., additional, Carvajal Palao, R., additional, Diaz Corte, C., additional, Ruiz Ortega, M., additional, Lopez-Larrea, C., additional, Yadav, A. K., additional, Bansal, D., additional, Kumar, V., additional, Minz, M., additional, Jha, V., additional, Kaminska, D., additional, Koscielska-Kasprzak, K., additional, Chudoba, P., additional, Mazanowska, O., additional, Banasik, M., additional, Zabinska, M., additional, Boratynska, M., additional, Lepiesza, A., additional, Korta, K., additional, Klinger, M., additional, Csohany, R., additional, Prokai, A., additional, Pap, D., additional, Balicza-Himer, N., additional, Vannay, A., additional, Fekete, A., additional, Kis-Petik, K., additional, Peti-Peterdi, J., additional, Szabo, A., additional, Masajtis-Zagajewska, A., additional, Muras, K., additional, Niewodniczy, M., additional, Nowicki, M., additional, Pascual, J., additional, Srinivas, T. R., additional, Chadban, S., additional, Citterio, F., additional, Henry, M., additional, Oppenheimer, F., additional, Lee, P.-C., additional, Tedesco-Silva, H., additional, Zeier, M., additional, Watarai, Y., additional, Dong, G., additional, Hexham, M., additional, Bernhardt, P., additional, Vincenti, F., additional, Rocchetti, M. T., additional, Su owicz, J., additional, Wojas-Pelc, A., additional, Ignacak, E., additional, Janda, K., additional, Krzanowski, M., additional, Su owicz, W., additional, Mitsuhashi, M., additional, Murakami, T., additional, Benso, A., additional, Leuning, D., additional, Reinders, M., additional, Lievers, E., additional, Duijs, J., additional, Van Zonneveld, A. J., additional, Van Kooten, C., additional, Engelse, M., additional, Rabelink, T., additional, Assounga, A., additional, Omarjee, S., additional, Ngema, Z., additional, Ersoy, A., additional, Gultepe, A., additional, Isiktas Sayilar, E., additional, Akalin, H., additional, Coskun, F., additional, Oner Torlak, M., additional, Ayar, Y., additional, Riegersperger, M., additional, Plischke, M., additional, Steinhauser, C., additional, Jallitsch-Halper, A., additional, Sengoelge, G., additional, Winkelmayer, W. C., additional, Sunder-Plassmann, G., additional, Foedinger, M., additional, Kaziuk, M., additional, Kuz'Niewski, M., additional, B Tkowska- Prokop, A., additional, Pa Ka, K., additional, Dumnicka, P., additional, Kolber, W., additional, and Su Owicz, W., additional

Published
2014
Full Text
View/download PDF

24. Cell signalling

Author

Tsuchiya, K., primary, Shiohira, S., additional, Sugiura, H., additional, Suzuki, M., additional, Okano, K., additional, Nitta, K., additional, Kaesler, N., additional, Immendorf, S., additional, Ouyang, C., additional, Carmeliet, P., additional, Floege, J., additional, Kruger, T., additional, Schlieper, G., additional, Georgescu, A., additional, Kalucka, J., additional, Olbrich, S., additional, Baumgartl, J., additional, Hackenbeck, T., additional, Eckardt, K.-U., additional, Weidemann, A., additional, Chmielewski, S., additional, Olejnik, A., additional, Sikorski, K., additional, Heemann, U., additional, Wesoly, J., additional, Bluyssen, H., additional, Baumann, M., additional, Mekahli, D., additional, Decuypere, J.-P., additional, Missiaen, L., additional, Levtchenko, E., additional, De Smedt, H., additional, Stasi, A., additional, Castellano, G., additional, Gigante, M., additional, Intini, A., additional, Pontrelli, P., additional, Divella, C., additional, Curci, C., additional, Grandaliano, G., additional, Gesualdo, L., additional, Vizza, D., additional, Perri, A., additional, Lofaro, D., additional, Toteda, P., additional, Lupinacci, S., additional, Leone, F., additional, Gigliotti, P., additional, Papalia, T., additional, Bonofiglio, R., additional, Vatazin, A. V., additional, Astakhov, P. V., additional, Zulkarnaev, A. B., additional, Parodi, E., additional, Verzola, D., additional, D'Amato, E., additional, Viazzi, F., additional, Gonnella, A., additional, Garneri, D., additional, Pontremoli, R., additional, Garibotto, G., additional, Chen, T.-H., additional, Chen, C.-H., additional, Chen, Y.-C., additional, Sue, Y.-M., additional, Cheng, C.-Y., additional, Guiying, L., additional, Ying, L., additional, Pozzoli, S., additional, Lino, M., additional, Delli Carpini, S., additional, Ferrandi, M., additional, Zerbini, G., additional, Simonini, M., additional, Zagato, L., additional, Molinari, I., additional, Citterio, L., additional, Manunta, P., additional, Feng, X., additional, Pan, X., additional, Wang, W., additional, Chen, N., additional, Chen, Y.-x., additional, Wang, W.-M., additional, Tanaka, S., additional, Yano, S., additional, Sugimoto, T., additional, Noh, H., additional, Yu, M. R., additional, Kim, H. J., additional, Woo, S. A., additional, Cho, Y. J., additional, Kwon, S. H., additional, Jeon, J. S., additional, Han, D. C., additional, Shimizu, H., additional, Yisireyili, M., additional, Nishijima, F., additional, Niwa, T., additional, Koh, E. S., additional, Chung, S., additional, Kim, S. J., additional, Yoon, H. E., additional, Park, C. W., additional, Chang, Y. S., additional, Shin, S. J., additional, Seong, E. Y., additional, Rhee, H., additional, Shin, M. J., additional, Yang, B. Y., additional, Jung, Y. S., additional, Lee, D. W., additional, Lee, S. B., additional, Kwak, I. S., additional, Kim, I. Y., additional, Sancho-Martinez, S. M., additional, Prieto-Garcia, L., additional, Lopez-Hernandez, F. J., additional, Lopez-Novoa, J. M., additional, Bae, E. H., additional, Choi, H. S., additional, Joo, S. Y., additional, Kim, I. J., additional, Kim, C. S., additional, Choi, J. S., additional, Ma, S. K., additional, Lee, J., additional, Kim, S. W., additional, Humanes, B., additional, Sonia, C., additional, Jado, J., additional, Mojena, M., additional, Lara, J., additional, Alvarez-Sala, L., additional, Tejedor, A., additional, Lazaro, A., additional, Wada, Y., additional, Iyoda, M., additional, Matsumoto, K., additional, Shindo-Hirai, Y., additional, Kuno, Y., additional, Yamamoto, Y., additional, Suzuki, T., additional, Shibata, T., additional, Akizawa, T., additional, Faubel, S., additional, Edelstein, C. L., additional, Cano Penalver, J. L., additional, de Frutos Garcia, S., additional, Griera Merino, M., additional, Luengo Rodriguez, A., additional, Garcia Jerez, A., additional, Bohorquez Magro, L., additional, Medrano, D., additional, Calleros Basilio, L., additional, Rodriguez Puyol, M., additional, Thilo, F., additional, Liu, Y., additional, Tepel, M., additional, Hsu, H.-H., additional, Chen, K.-H., additional, Hung, C.-C., additional, Yang, C.-W., additional, Endlich, N., additional, Lin, J.-L., additional, Pavenstadt, H., additional, Rodrigues Diez, R. R., additional, Mezzano, S., additional, Ruiz-Ortega, M., additional, Rodrigues Diez, R., additional, Lavoz, C., additional, Nakayama, Y., additional, Fukami, K., additional, Yamagishi, S.-i., additional, Obara, N., additional, Yokoro, M., additional, Ando, R., additional, Kaida, Y., additional, Toyonaga, M., additional, Kaifu, K., additional, Takeuchi, M., additional, Ueda, S., additional, Okuda, S., additional, Daenen, K., additional, Hoylaerts, M. F., additional, Bammens, B., additional, Liu, J., additional, Zhong, F., additional, Dai, Q., additional, Xu, L., additional, Zaravinos, A., additional, and Deltas, C. C., additional

Published
2013
Full Text
View/download PDF

25. Hormones

Author

Gatti, G., primary, Lanzani, C., additional, Messaggio, E., additional, Casamassima, N., additional, Hamlyn, J., additional, Simonini, M., additional, Manunta, P., additional, Perri, A., additional, Vizza, D., additional, Lofaro, D., additional, Gigliotti, P., additional, Leone, F., additional, Papalia, T., additional, Bonofiglio, R., additional, Gawrys, O., additional, Gawarecka, K., additional, Swiezewska, E., additional, Masnyk, M., additional, Chmielewski, M., additional, Kompanowska-Jezierska, E., additional, Apponi, F., additional, Sinibaldi, V., additional, Giuliani, A., additional, Baldinelli, M., additional, Luciani, R., additional, Giordano, F., additional, Panzieri, G., additional, Punzo, G., additional, Mene, P., additional, Pirozzi, N., additional, Dusilova Sulkova, S., additional, Horacek, J., additional, Safranek, R., additional, Kalousova, M., additional, Malirova, E., additional, Dlabalova, B., additional, Kubisova, M., additional, Zak, P., additional, Sirotina, N., additional, Fidchenko, Y., additional, Smirnova, O., additional, Moraes, C. F., additional, Marinho, S. M., additional, Stockler-Pinto, M. B., additional, Barros, A. F., additional, Mafra, D., additional, Inoue, M., additional, Saito, T., additional, Ueno, K., additional, Yoshimura, A., additional, Yamamoto, H., additional, Saito, O., additional, Kusano, E., additional, Leal, V. O., additional, Barroso, S. G., additional, Rocha, G. S., additional, Boaventura, G. T., additional, Molsted, S., additional, Andersen, J. L., additional, Eidemak, I., additional, Harrison, A., additional, and Jorgensen, N., additional

Published
2013
Full Text
View/download PDF

26. Transplantation - clinical studies II

Author

Marques, I. B., primary, Silva, R. d. M., additional, Moraes, C. E., additional, Azevedo, L. S., additional, Nahas, W. C., additional, David-Neto, E., additional, Furmanczyk-Zawiska, A., additional, Baczkowska, T., additional, Chmura, A., additional, Szmidt, J., additional, Durlik, M., additional, Joslin, J., additional, Blaker, P., additional, White, B., additional, Marinaki, A., additional, Sanderson, J., additional, Goldsmith, D. J., additional, Medani, S., additional, Traynor, C., additional, Mohan, P., additional, Little, D., additional, Conlon, P., additional, Molina, M., additional, Gonzalez, E., additional, Gutierrez, E., additional, Sevillano, A., additional, Polanco, N., additional, Morales, E., additional, Hernandez, A., additional, Praga, M., additional, Morales, J. M., additional, Andres, A., additional, Park, S. J., additional, Kim, T. H., additional, Kim, Y. W., additional, Kim, Y. H., additional, Kang, S. W., additional, Kujawa-Szewieczek, A., additional, Szotowska, M., additional, Kuczera, P., additional, Chudek, J., additional, Wiecek, A., additional, Kolonko, A., additional, Mahrova, A., additional, Svagrova, K., additional, Bunc, V., additional, Stollova, M., additional, Teplan, V., additional, Hundt, F., additional, van Heteren, P., additional, Woitas, R., additional, Cavallo, M. C., additional, Sepe, V., additional, Conte, F., additional, Albrizio, P., additional, Bottazzi, A., additional, Geraci, P. M., additional, Alpay, N., additional, Gumber, M. R., additional, Kute, V. B., additional, Vanikar, A. V., additional, Patel, H. V., additional, Shah, P. R., additional, Engineer, D. P., additional, Trivedi, H. L., additional, Golebiewska, J. E., additional, Debska-Slizien, A., additional, Rutkowski, B., additional, Matias, P., additional, Martins, A. R., additional, Raposo, L., additional, Jorge, C., additional, Weigert, A., additional, Birne, R., additional, Bruges, M., additional, Adragao, T., additional, Almeida, M., additional, Mendes, M., additional, Machado, D., additional, Masin-Spasovska, J., additional, Dohcev, S., additional, Stankov, O., additional, Stavridis, S., additional, Saidi, S., additional, Dejanova, B., additional, Rambabova-Busletic, I., additional, Dejanov, P., additional, Spasovski, G., additional, Nho, K. W., additional, Han, D. J., additional, Park, S.-K., additional, Kim, S. B., additional, Fenoglio, R., additional, Lazzarich, E. E., additional, Cagna, D., additional, Cena, T., additional, Conti, N., additional, Quaglia, M., additional, Radin, E., additional, Izzo, C., additional, Stratta, P., additional, Oh, I. H., additional, Park, J.-S., additional, Lee, C. H., additional, Kang, C. M., additional, Kim, G.-H., additional, Leone, F., additional, Lofaro, D., additional, Gigliotti, P., additional, Lupinacci, S., additional, Toteda, P., additional, Vizza, D., additional, Perri, A., additional, Papalia, T., additional, Bonofiglio, R., additional, di Loreto, P., additional, de Silvestro, L., additional, Montanaro, D., additional, Martino, F., additional, Sandrini, S., additional, Minetti, E., additional, Cabiddu, G., additional, Yildirim, T., additional, Yilmaz, R., additional, Turkmen, E., additional, Abudalal, A., additional, Altindal, M., additional, Ertoy-Baydar, D., additional, Erdem, Y., additional, Panuccio, V., additional, Tripepi, R., additional, Parlongo, G., additional, Versace, M. C., additional, Politi, R., additional, Zoccali, C., additional, Mallamaci, F., additional, Porrini, E., additional, Silva, I., additional, Diaz, J., additional, Ibernon, M., additional, Moreso, F., additional, Benitez, R., additional, Delgado Mallen, P., additional, Osorio, J., additional, Lauzurica, R., additional, Torres, A., additional, Ersoy, A., additional, Koca, N., additional, Gullu Koca, T., additional, Kirhan, E., additional, Sarandol, E., additional, Ersoy, C., additional, Dirican, M., additional, Milne, J., additional, Suter, V., additional, Mikhail, A., additional, Akalin, H., additional, Dizdar, O., additional, Pascual, J., additional, Torio, A., additional, Garcia, C., additional, Hernandez, J., additional, Perez-Saez, M. J., additional, Mir, M., additional, Anna, F., additional, Crespo, M., additional, Carta, P., additional, Zanazzi, M., additional, Antognoli, G., additional, Di Maria, L., additional, Caroti, L., additional, Ray, D. S., additional, Mukherjee, K., additional, Bohidar, N. P., additional, Pattanaik, A., additional, Das, P., additional, Thukral, S., additional, Kimura, T., additional, Yagisawa, T., additional, Ishikawa, N., additional, Sakuma, Y., additional, Fujiwara, T., additional, Nukui, A., additional, Gavela, E. E., additional, Sancho, A. A., additional, Kanter, J. J., additional, Avila, A. A., additional, Beltran, S. S., additional, Pallardo, L. L., additional, Dawoud, F. G., additional, Aithal, V., additional, Majernikova, M., additional, Rosenberger, J., additional, Prihodova, L., additional, Nagyova, I., additional, Jarcuskova, M., additional, Roland, R., additional, Groothoff, J. W., additional, van Dijk, J. P., additional, van Agteren, M., additional, de Weerd, A., additional, van de Wetering, J., additional, IJzermans, J., additional, Betjes, M., additional, Weimar, W., additional, Popoola, J., additional, Reed, A., additional, Tavarro, R., additional, Chryssanthopoulou, C., additional, MacPhee, I., additional, Mayor, M., additional, Franco, S., additional, Jara, P., additional, Ayala, R., additional, Orue, M. G., additional, Martinez, A., additional, Martinez, M., additional, Wasmouth, N., additional, Arik, G., additional, Yasar, A., additional, Yilmaz, S., additional, Arici, M., additional, Bihari Bansal, S., additional, Pokhariyal, S., additional, Jain, S., additional, Sethi, S., additional, Ahlawat, R., additional, Kher, V., additional, Martins, L. S., additional, Aguiar, P., additional, Dias, L., additional, Fonseca, I., additional, Henriques, A. C., additional, Cabrita, A., additional, Davide, J., additional, Sparkes, T. M., additional, Trofe-Clark, J., additional, Reese, P. P., additional, Jakobowski, D., additional, Goral, S., additional, Doll, S. L., additional, Abt, P. L., additional, Sawinski, D., additional, MBloom, R. D., additional, Knap, B., additional, Lukac, J., additional, Lukin, M., additional, Majcen, I., additional, Pavlovec, F., additional, Kandus, A., additional, Bren, A. F., additional, Kong, J. M., additional, Jeong, J. H., additional, Ahn, J., additional, Lee, D. R., additional, Son, S. H., additional, Kim, B. C., additional, Choi, W. Y., additional, Whang, E. J., additional, Czajka, B., additional, Malgorzewicz, S., additional, Panizo, N., additional, Rengel, M. A., additional, Vega, A., additional, Abad, S., additional, Tana, L., additional, Arroyo, D., additional, Rodriguez-Ferrero, M., additional, Perez de Jose, A., additional, Lopez-Gomez, J. M., additional, Koutroutsos, K., additional, Sackey, J., additional, Paolini, L., additional, Ramkhelawon, R., additional, Chowrimootoo, M., additional, Whelan, D., additional, Slatinska, J., additional, Honsova, E., additional, Wohlfahrtova, M., additional, Slimackova, E., additional, Rajnochova, S. B., additional, Viklicky, O., additional, Yankovoy, A., additional, Smith, I. S. J., additional, Wylie, E., additional, Ruiz-Esteban, P., additional, Lopez, V., additional, Garcia-Frias, P., additional, Cabello, M., additional, Gonzalez-Molina, M., additional, Vozmediano, C., additional, Hernandez, D., additional, Pavlovic, J., additional, Radivojevic, D., additional, Lezaic, V., additional, Simic-Ogrizovic, S., additional, Lausevic, M., additional, Naumovic, R., additional, Sakhuja, V., additional, Gundlapalli, S., additional, Rathi, M., additional, Jha, V., additional, Kohli, H. S., additional, Sharma, A., additional, Minz, M., additional, Nimgirova, A., additional, Esayan, A., additional, Kayukov, I., additional, Zuyeva, E., additional, Bilen, Y., additional, Cankaya, E., additional, Keles, M., additional, Gulcan, E., additional, Turkeli, M., additional, Albayrak, B., additional, Uyanik, A., additional, Yildirim, R., additional, Molitor, N., additional, Praktiknjo, M., additional, Abeygunaratne, T. N., additional, Balasubramanian, S., additional, Baker, R., additional, Nicholson, T., additional, Toprak, O., additional, Sari, Y., additional, Keceli, S., additional, Kurt, H., additional, Rocha, A., additional, Malheiro, J., additional, Pedroso, S., additional, Henriques, A., additional, Nihei, C., additional, Bacelar Marques, I., additional, Seguro, C. A., additional, Mate, G., additional, Martin, N., additional, Colon, L., additional, Casellas, L., additional, Garangou, D., additional, de la Torre, M., additional, Torguet, P., additional, Garcia, I., additional, Calabia, J., additional, Valles, M., additional, Pruthi, R., additional, Calestani, M., additional, Leydon, G., additional, Ravanan, R., additional, Roderick, P., additional, Korkmaz, S., additional, and Gulten, S., additional

Published
2013
Full Text
View/download PDF

30. Sperm metabolism in pigs: a role for peroxisome proliferator-activated receptor gamma (PPARγ).

Author

Santoro, M., Guido, C., De Amicis, F., Sisci, D., Vizza, D., Gervasi, S., Carpino, A., and Aquila, S.

Subjects
PEROXISOME proliferator-activated receptors, SPERMATOZOA, METABOLISM, LABORATORY swine, HOMEOSTASIS, PROSTAGLANDINS, GENE expression
Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear hormone receptor expressed predominantly in adipose tissue, also implicated in energy homeostasis. In this study, we used western blotting and immunofluorescence techniques to demonstrate for the first time that pig spermatozoa express PPARγ. To Investigate the functional role of PPARγ in pig sperm, we evaluated its action on different events that characterize the biology of sperm cells, i.e. motility, capacitation, viability and acrosome reaction, using the PPARγ-agonist 15-deoxy-12,14-prostaglandin J2 (PGJ2). In responses to PGJ2 treatment, motility, cholesterol efflux and tyrosine phosphorylation were increased, which broadens the role of PPARγ from that previously described in the literature, as it also acts to improve sperm functionality. To further our understanding of the significance of PPARγ in pig sperm, we focused its effects on lipid and glucose metabolism. Evaluation of triglyceride content and lipase, acyl-CoA dehydrogenase and G6PDH activities suggests that PPARγ induces energy expenditure in pig spermatozoa. These data represent a meaningful advance in the field of sperm energy metabolism. Taken together, our results demonstrate for the first time that PPARγ is expressed by pig sperm, thus improving its functionalities in terms of motility, capacitation, acrosome reaction, survival and metabolism. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

33. Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base

Author

Federica Toto, Elisabetta Salvioni, Damiano Magrì, Susanna Sciomer, Massimo Piepoli, Roberto Badagliacca, Arianna Galotta, Nikita Baracchini, Stefania Paolillo, Ugo Corrà, Rosa Raimondo, Rocco Lagioia, Pasquale Perrone Filardi, Annamaria Iorio, Michele Senni, Michele Correale, Mariantonietta Cicoira, Enrico Perna, Marco Metra, Marco Guazzi, Giuseppe Limongelli, Gianfranco Sinagra, Gianfranco Parati, Gaia Cattadori, Francesco Bandera, Maurizio Bussotti, Massimo Mapelli, Manlio Cipriani, Alice Bonomi, Gonçalo Cunha, Federica Re, Carlo Vignati, Andrea Garascia, Carlo Lombardi, Angela B. Scardovi, Andrea Passantino, Michele Emdin, Claudio Passino, Caterina Santolamazza, Davide Girola, Denise Zaffalon, Dario Vizza, Fabiana De Martino, Piergiuseppe Agostoni, Toto, Federica, Salvioni, Elisabetta, Magrì, Damiano, Sciomer, Susanna, Piepoli, Massimo, Badagliacca, Roberto, Galotta, Arianna, Baracchini, Nikita, Paolillo, Stefania, Corrà, Ugo, Raimondo, Rosa, Lagioia, Rocco, Filardi, Pasquale Perrone, Iorio, Annamaria, Senni, Michele, Correale, Michele, Cicoira, Mariantonietta, Perna, Enrico, Metra, Marco, Guazzi, Marco, Limongelli, Giuseppe, Sinagra, Gianfranco, Parati, Gianfranco, Cattadori, Gaia, Bandera, Francesco, Bussotti, Maurizio, Mapelli, Massimo, Cipriani, Manlio, Bonomi, Alice, Cunha, Gonçalo, Re, Federica, Vignati, Carlo, Garascia, Andrea, Lombardi, Carlo, Scardovi, Angela B, Passantino, Andrea, Emdin, Michele, Passino, Claudio, Santolamazza, Caterina, Girola, Davide, Zaffalon, Denise, Vizza, Dario, De Martino, Fabiana, Agostoni, Piergiuseppe, Toto, F., Salvioni, E., Magri, D., Sciomer, S., Piepoli, M., Badagliacca, R., Galotta, A., Baracchini, N., Paolillo, S., Corra, U., Raimondo, R., Lagioia, R., Filardi, P. P., Iorio, A., Senni, M., Correale, M., Cicoira, M., Perna, E., Metra, M., Guazzi, M., Limongelli, G., Sinagra, G., Parati, G., Cattadori, G., Bandera, F., Bussotti, M., Mapelli, M., Cipriani, M., Bonomi, A., Cunha, G., Re, F., Vignati, C., Garascia, A., Lombardi, C., Scardovi, A. B., Passantino, A., Emdin, M., Passino, C., Santolamazza, C., Girola, D., Zaffalon, D., Vizza, D., De Martino, F., and Agostoni, P.

Subjects
Renin angiotensin aldosterone system inhibitor, Prognosi, Heart failure, Hyperkalemia, Prognosis, Settore MED/11 - Malattie dell'Apparato Cardiovascolare, Cardiology and Cardiovascular Medicine
Abstract

Background: The prognostic role of moderate hyperkalemia in reduced ejection fraction (HFrEF) patients is still controversial. Despite this, it affects the use of renin–angiotensin–aldosterone system inhibitors (RAASi) with therapy down-titration or discontinuation. Objectives: Aim of the study was to assess the prognostic impact of moderate hyperkalemia in chronic HFrEF optimally treated patients. Methods and results: We retrospectively analyzed MECKI (Metabolic Exercise test data combined with Cardiac and Kidney Indexes) database, with median follow-up of 4.2 [IQR 1.9–7.5] years. Data on K+ levels were available in 7087 cases. Patients with K+ plasma level ≥ 5.6 mEq/L and < 4 mEq/L were excluded. Remaining patients were categorized into normal >4 and < 5 mEq/L (n = 4826, 68%) and moderately high ≥5.0 and ≤ 5.5 mEq/L (n = 496, 7%) K+. Then patients were matched by propensity score in 484 couplets of patients. MECKI score value was 7% [IQR 3.1–14.1%] and 7.3% [IQR 3.4–15%] (p = 0.678) in patients with normal and moderately high K+ values while cardiovascular mortality events at two years follow-up were 41 (4.2%) and 33 (3.4%) (p = 0.333) in each group respectively. Conclusions: Moderate hyperkalemia does not influence patients' outcome in a large cohort of ambulatory HFrEF patients.

Published
2023

34. Health-related quality of life and symptom concordance between patients and physicians in pulmonary arterial hypertension in the United States, Europe, and Japan.

Author

White RJ, Vizza D, Klok R, Lautsch D, Harley J, and Small M

Abstract

This study involved analysis of a real world, cross-sectional survey of physicians and their patients with pulmonary arterial hypertension (PAH). Physician and patient symptom concordance was assessed and patients self-reported Health-Related Quality of Life (HRQoL). Data were drawn from the Adelphi PAH Disease Specific Programme (DSP)™ in the United States, France, Germany, Italy, Spain, United Kingdom, and Japan, between March and August 2022. EQ-5D 5L utility, EQ-5D Visual Analogue Scale (VAS) scores, and emPHasis-10 (e10) HRQoL scores were reported by patients and physician-patient symptom concordance which was assessed with Cohen's Weighted Kappa (κ) analysis. Of 628 PAH patients, the mean (SD) EQ-5D VAS and e10 scores were 66 (17) and 23 (11). Data was stratified by World Health Organization Functional Class (WHO-FC). As WHO-FC increased, EQ-5D utility and VAS scores decreased and e10 scores increased, indicating poorer patient-reported HRQoL. Symptom concordance varied, ranging from κ = 0.11 - 0.57 (slight-moderate agreement), and physicians frequently underestimated the presence and severity of patient-reported symptoms. Future research should aim to bridge this gap between patient and physician understanding of HRQoL and the symptom burden associated with PAH., Competing Interests: Declaration of Competing Interest RK and DL are employees of Merck & Co., Inc. JH and MS are employees of Adelphi Real World. JW and DV has received consultancy payments from Merck & Co., Inc., (Copyright © 2024. Published by Elsevier Ltd.)

Published
2024
Full Text
View/download PDF

35. OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry.

Author

Inciardi RM, Vaduganathan M, Lombardi CM, Gussago C, Agostoni P, Ameri P, Aspromonte N, Calò L, Cameli M, Carluccio E, Carugo S, Cipriani M, De Caterina R, De Ferrari GM, Emdin M, Fornaro A, Guazzi M, Iacoviello M, Imazio M, La Rovere MT, Leonardi S, Maccallini M, Masarone D, Moschini L, Palazzuoli A, Patti G, Pedretti RFE, Perrone Filardi P, Piepoli MF, Potena L, Salzano A, Sciacqua A, Senni M, Sinagra G, Specchia C, Taddei S, Vizza D, Savarese G, Rosano G, Volterrani M, and Metra M

Subjects
Humans, Prospective Studies, Stroke Volume physiology, Guideline Adherence, Female, Male, Italy epidemiology, Heart Failure drug therapy, Registries
Abstract

Aims: Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM-HF) registry is designed to evaluate the prevalence of evidence-based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real-world population of consecutive patients with HF across the whole ejection fraction spectrum and among different clinical phenotypes., Methods: The OPTIPHARM-HF registry (NCT06192524) is a prospective, multicenter, observational, national study of adult patients with symptomatic HF, as defined by current international guidelines, regardless of ejection fraction. Both outpatients and inpatients with chronic and acute decompensated HF will be recruited. The study will enroll up to 2500 patients with chronic HF at approximately 35 Italian HF centres. Patients will be followed for a maximum duration of 24 months. The primary objective of the OPTIPHARM-HF registry is to assess prescription and adherence to evidence-based guideline-directed medical therapy (GDMT) in patients with HF. The primary outcome is to describe the prevalence of GDMT use according to target guideline recommendation. Secondary objectives include implementation of comorbidity treatment, evaluation of sequence of treatment introduction and up-titration, description of GDMT implementation in the specific HF population, main causes of GDMT underuse, and assessment of cumulative rate of cardiovascular events., Conclusion: The OPTIPHARM-HF registry will provide important implications for improving patient care and adoption of recommended medical therapy into clinical practice among HF patients., (© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

36. Prognostic value of deep echocardiographic phenotyping in pulmonary arterial hypertension.

Author

Ghio S, Badagliacca R, Acquaro M, Filomena D, Recchioni T, Papa S, Colombo D, Ditali V, Carrozzi C, Greco A, Turco A, Breviario F, Benza R, Vizza D, and Scelsi L

Abstract

Background: A novel approach to derive prognostic information from echocardiography in pulmonary arterial hypertension (PAH) is to define a phenotype of right heart function combining standard echocardiographic parameters which describe right ventricular pump function and systemic venous congestion. We tested the hypothesis that the combination of advanced strain imaging parameters could yield high prognostic accuracy., Methods: This was a prospective observational study with a single centre derivation cohort and a second centre validation cohort. The derivation cohort included 49 naive PAH patients who underwent right heart catheterisation and echocardiographic evaluation at baseline and 4-12 months after diagnosis. The validation cohort included 83 prevalent PAH patients who underwent the same examinations at 12 months after diagnosis. We stratified the risk of the derivation cohort according to three models: Model 1, based on haemodynamic parameters; Model 2, based on standard echocardiographic parameters; and Model 3, based on advanced echocardiographic parameters. The median follow-up period was 21 months; the end point of the analysis was clinical worsening., Results: In the derivation cohort, haemodynamic and echocardiographic parameters obtained at diagnosis were not associated with outcome, whereas a significant association was observed at first reassessment. Model 3 yielded a better predictive accuracy (Harrell's C index 0.832) as compared to Model 2 (Harrell's C index 0.667), and to Model 1 (Harrell's C index 0.713). The validation cohort confirmed the accuracy of Model 3., Conclusions: A comprehensive assessment of right heart function using right ventricular strain, right atrial reservoir strain and degree of tricuspid regurgitation provides accurate prognostic information in prevalent PAH patients., Competing Interests: Conflict of interest: S. Ghio reports personal fees from MSD and Ferrer, outside the submitted work. Conflict of interest: R. Badagliacca reports personal fees from UT, Dompè, Ferrer, Bayer, MSD and AOP Orphan Pharmaceuticals, outside the submitted work. Conflict of interest: R. Benza reports receiving grants from Actelion, Bayer AG, Bellerophon Therapeutics and Eiger Biopharmaceuticals, outside the submitted work. Conflict of interest: D. Vizza reports personal fees from GSK, UT, Dompè, Bayer and MSD, outside the submitted work. Conflict of interest: Other authors have nothing to disclose., (Copyright ©The authors 2024.)

Published
2024
Full Text
View/download PDF

37. Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base.

Author

Toto F, Salvioni E, Magrì D, Sciomer S, Piepoli M, Badagliacca R, Galotta A, Baracchini N, Paolillo S, Corrà U, Raimondo R, Lagioia R, Filardi PP, Iorio A, Senni M, Correale M, Cicoira M, Perna E, Metra M, Guazzi M, Limongelli G, Sinagra G, Parati G, Cattadori G, Bandera F, Bussotti M, Mapelli M, Cipriani M, Bonomi A, Cunha G, Re F, Vignati C, Garascia A, Lombardi C, Scardovi AB, Passantino A, Emdin M, Passino C, Santolamazza C, Girola D, Zaffalon D, Vizza D, De Martino F, and Agostoni P

Subjects
Humans, Retrospective Studies, Stroke Volume, Renin-Angiotensin System, Potassium, Heart Failure, Hyperkalemia diagnosis, Hyperkalemia epidemiology
Abstract

Background: The prognostic role of moderate hyperkalemia in reduced ejection fraction (HFrEF) patients is still controversial. Despite this, it affects the use of renin-angiotensin-aldosterone system inhibitors (RAASi) with therapy down-titration or discontinuation., Objectives: Aim of the study was to assess the prognostic impact of moderate hyperkalemia in chronic HFrEF optimally treated patients., Methods and Results: We retrospectively analyzed MECKI (Metabolic Exercise test data combined with Cardiac and Kidney Indexes) database, with median follow-up of 4.2 [IQR 1.9-7.5] years. Data on K + levels were available in 7087 cases. Patients with K + plasma level ≥ 5.6 mEq/L and < 4 mEq/L were excluded. Remaining patients were categorized into normal >4 and < 5 mEq/L (n = 4826, 68%) and moderately high ≥5.0 and ≤ 5.5 mEq/L (n = 496, 7%) K + . Then patients were matched by propensity score in 484 couplets of patients. MECKI score value was 7% [IQR 3.1-14.1%] and 7.3% [IQR 3.4-15%] (p = 0.678) in patients with normal and moderately high K + values while cardiovascular mortality events at two years follow-up were 41 (4.2%) and 33 (3.4%) (p = 0.333) in each group respectively., Conclusions: Moderate hyperkalemia does not influence patients' outcome in a large cohort of ambulatory HFrEF patients., Competing Interests: Declaration of Competing Interest None to declare., (Copyright © 2022 Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

38. The intention to get COVID-19 vaccine and vaccine uptake among cancer patients: An extension of the theory of planned behaviour (TPB).

Author

Servidio R, Malvaso A, Vizza D, Valente M, Campagna MR, Iacono ML, Martin LR, and Bruno F

Subjects
COVID-19 Vaccines, Female, Health Knowledge, Attitudes, Practice, Humans, Intention, Male, Vaccination psychology, COVID-19 prevention & control, Neoplasms, Vaccines
Abstract

The psychosocial impact of coronavirus disease 2019 (COVID-19) on human life is well-known. Although vaccine protection represents an effective way to control the spread of the virus, vaccination hesitancy may decrease individuals' willingness to get vaccinated, including among cancer patients. Therefore, the objective of the current study was to examine the predictors of cancer patients' intentions to receive COVID-19 vaccinations and vaccine uptake, using and integrating the theory of planned behaviour (TPB) and the health belief model (HBM). A sample of 276 Italian cancer patients (54% female and 46% male) ranging from 19 to 85 years (M = 49.64, SD = 11.53) was recruited by administering an online questionnaire. The current study results showed that cancer patients with higher trust in health authorities tended to have vaccine-positive subjective norms, perceived that vaccination was under their control, and viewed COVID-19 vaccines positively. On the other hand, the perceived risk of COVID-19 was related to subjective norms but not to perceived behavioural control or attitudes towards COVID-19 vaccination. The current study reveals that TPB variables can function effectively as mediators between perceived risk, trust, and intention to vaccinate but at different levels. Together, these findings suggest that effective interventions (both public health messaging and personal medical communications) should focus on enhancing trust in health authorities, while at the same time endeavouring to highlight subjective norms that are vaccine-positive., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

39. Positive personal resources and psychological distress during the COVID-19 pandemic: resilience, optimism, hope, courage, trait mindfulness, and self-efficacy in breast cancer patients and survivors.

Author

Chiesi F, Vizza D, Valente M, Bruno R, Lau C, Campagna MR, Lo Iacono M, and Bruno F

Subjects
Depression epidemiology, Depression etiology, Depression psychology, Female, Humans, Pandemics, Self Efficacy, Stress, Psychological epidemiology, Stress, Psychological etiology, Stress, Psychological psychology, Survivors, Breast Neoplasms therapy, COVID-19, Courage, Mindfulness, Psychological Distress, Resilience, Psychological
Abstract

Purpose: This study aims to understand the association between positive personal resources (i.e., optimism, hope, courage, trait mindfulness, and self-efficacy), resilience, and psychological distress (i.e., anxiety, depression, stress) in women with breast cancer and breast cancer survivors during the COVID-19 pandemic. We hypothesized that personal positive resources can directly influence resilience, which in turn prevented psychological distress., Methods: The research sample consisted of 409 Italian women (49% patients, 51% survivors) who were administered a questionnaire to assess positive resources, resiliency, and distress. structural equation model (SEM) analysis was carried out to confirm the hypothetical-theoretical model., Results: Personal positive resources had a direct positive effect on resilience, which prevented from distress. These results were observed across cancer patients and survivors, and regardless the level of direct exposure to COVID-19., Conclusions: In both patients and survivors, the relationships between positive personal resources, resilience, and psychological distress is strong enough to be not influenced by the level of exposure to COVID-19 and despite COVID-19 pandemic caused the disruption of active treatment plans and delays in routine check-ups., Implications for Cancer Survivors: Implications of this study suggest the urgency to screen positive resources and to identify women with lower resilience and a potentially higher susceptibility to develop psychological distress. For these women, our findings suggest the implementation of psychological interventions that build resilience., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

40. Assessing the fear of recurrence using the Cancer Worry Scale in a sample of Italian breast cancer survivors.

Author

Chirico A, Vizza D, Valente M, Iacono ML, Campagna MR, Palombi T, Alivernini F, Lucidi F, and Bruno F

Subjects
Anxiety diagnosis, Anxiety epidemiology, Anxiety etiology, Fear, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Reproducibility of Results, Surveys and Questionnaires, Breast Neoplasms, Cancer Survivors
Abstract

Purpose: The fear of cancer recurrence (FCR) is one of the most reported problems by cancer survivors. A valid instrument to detect this issue could be useful to identify cancer survivors who are more vulnerable to developing FCR and related adverse outcomes (e.g., anxiety). The present study aimed to evaluate FCR in a sample of Italian breast cancer survivors using an Italian version of the 8-item Cancer Worry Scale (CWS) in order to establish a cut-off for the use in clinical settings., Methods: The participants were 119 breast cancer survivors (mean age 47.7 years) at least 1 year after their primary treatment. An exploratory factor analysis (EFA) of CWS, internal reliability of CWS, concurrent and divergent validity using a bivariate correlation between the key measures of the study (i.e., FCR, anxiety, depression, fatigue, and self-efficacy), and ROC analysis of CWS were performed., Results: Fit indices for the EFA were considered acceptable and showed a two-factor structure-labeled cancer worries and worries impact. The reliability of the two factors showed a Cronbach's alpha coefficient greater than 0.90. The CWS was positively related to anxiety, depression, fatigue, and negatively related to perceived self-efficacy. The best cut-off score was 24 versus 25, with a sensitivity of 74% and a specificity of 85%., Conclusions: The CWS is a valid questionnaire to assess FCR among breast cancer survivors. The present study provides an overview of the relationship between CWS and the adverse outcomes related to FCR and coping strategies adopted to face it., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Published
2022
Full Text
View/download PDF

41. Rapamycin promotes autophagy cell death of Kaposi's sarcoma cells through P75NTR activation.

Author

Lupinacci S, Perri A, Toteda G, Vizza D, Lofaro D, Pontrelli P, Stallone G, Divella C, Tessari G, La Russa A, Zaza G, and Bonofiglio R

Subjects
Apoptosis, Autophagy, Humans, Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases metabolism, Sarcoma, Kaposi pathology, Sirolimus pharmacology
Abstract

The mammalian target of rapamycin inhibitor (mTOR-I) Rapamycin, a drug widely used in kidney transplantation, exerts important anti-cancer effects, particularly in Kaposi's Sarcoma (KS), through several biological interactions. In this in vivo and in vitro study, we explored whether the activation of the autophagic pathway through the low-affinity receptor for nerve growth factor, p75 NTR , may have a pivotal role in the anti-cancer effect exerted by Rapamycin in S. Our Kimmunohistochemistry results revealed a significant hyper-activation of the autophagic pathway in KS lesions. In vitro experiments on KS cell lines showed that Rapamycin exposure reduced cell viability by increasing the autophagic process, in the absence of apoptosis, through the transcriptional activation of p75 NTR via EGR1. Interestingly, p75 NTR gene silencing prevented the increase of the autophagic process and the reduction of cell viability. Moreover, p75 NTR activation promoted the upregulation of phosphatase and tensin homolog (PTEN), a tumour suppressor that modulates the PI3K/Akt/mTOR pathway. In conclusion, our in vitro data demonstrated, for the first time, that in Kaposi's sarcoma, autophagy triggered by Rapamycin through p75 NTR represented a major mechanism by which mTOR inhibitors may induce tumour regression. Additionally, it suggested that p75 NTR protein analysis could be proposed as a new potential biomarker to predict response to Rapamycin in kidney transplant recipients affected by Kaposi's sarcoma., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

43. NFKB1 promoter polymorphism: A new predictive marker of cytomegalovirus infection after kidney transplantation.

Author

Leone F, Gigliotti P, La Russa A, Lofaro D, Perri A, Vizza D, Lupinacci S, Toteda G, Bonofiglio M, Presta P, Talarico R, Aquino B, and Bonofiglio R

Subjects
Adult, Biomarkers analysis, Cytomegalovirus isolation & purification, Cytomegalovirus Infections epidemiology, Cytomegalovirus Infections genetics, Cytomegalovirus Infections virology, Female, Genetic Predisposition to Disease, Genetic Testing methods, Humans, INDEL Mutation, Incidence, Male, Middle Aged, Polymorphism, Genetic, Postoperative Complications epidemiology, Postoperative Complications genetics, Postoperative Complications virology, Predictive Value of Tests, Preoperative Care methods, Prognosis, Cytomegalovirus Infections diagnosis, Kidney Transplantation adverse effects, NF-kappa B p50 Subunit genetics, Postoperative Complications diagnosis, Promoter Regions, Genetic genetics
Abstract

Introduction: Cytomegalovirus (CMV) infection represents a common cause of morbidity and mortality in kidney transplant recipients (KTR). The NF-kB signaling pathway is highly involved in the pathogenesis of CMV infection. The -94ins/delATTG functional polymorphism in the promoter of NFKB1 has been associated with low intracellular levels of the protein and high incidence of inflammatory and autoimmune disease. In this study, we evaluated the association of this NFKB1 polymorphism with the risk of CMV infection., Methods: CMV infection was defined as virus isolation or detection of viral antigens or nucleic acid in any body fluid or tissue specimen. Using Cox regression and survival analysis, we analyzed the association between the polymorphism and CMV infection as well as recurrence in the first 12 months after transplantation., Results: We analyzed the -94ins/delATTG NFKB1 polymorphism of 189 KTRs. The 65% of CMV infections occurred in ins/ins group. Survival free from CMV infection was 54.7% for ins/ins group and 79.4% for deletion carriers one year after transplantation (P < 0.0001). At multivariate regression, deletion carriers showed a lower risk of CMV infection and recurrence with respect to ins/ins KTRs (HR = 0.224 P = 0.0002; HR = 0.307, P = 0.012, respectively)., Conclusions: In conclusion, pretransplantation screening for NFKB1 -94ins/delATTG polymorphism may predict CMV infection and improve the management of patients at higher risk of infection in the post-transplant period., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2019
Full Text
View/download PDF

44. An Olive Leaf Extract Rich in Polyphenols Promotes Apoptosis in Cervical Cancer Cells by Upregulating p21 Cip/WAF1 Gene Expression.

Author

Vizza D, Lupinacci S, Toteda G, Puoci F, Ortensia I P, De Bartolo A, Lofaro D, Scrivano L, Bonofiglio R, La Russa A, Bonofiglio M, and Perri A

Subjects
Apoptosis drug effects, Cell Proliferation drug effects, Female, Gene Expression drug effects, HeLa Cells, Humans, Up-Regulation drug effects, Uterine Cervical Neoplasms genetics, Uterine Cervical Neoplasms metabolism, Uterine Cervical Neoplasms pathology, Antineoplastic Agents, Phytogenic pharmacology, Olea chemistry, Plant Extracts pharmacology, Polyphenols pharmacology, Uterine Cervical Neoplasms drug therapy, p21-Activated Kinases metabolism
Abstract

Most of the common drugs used to treat the cervical cancer, which main etiological factor is the HPV infection, cause side effects and intrinsic/acquired resistance to chemotherapy. In this study we investigated whether an olive leaf extract (OLE), rich in polyphenols, was able to exert anti-tumor effects in human cervical cancer cells (HeLa). MTT assay results showed a reduction of HeLa cells viability OLE-induced, concomitantly with a gene and protein down-regulation of Cyclin-D1 and an up-regulation of p21, triggering intrinsic apoptosis. OLE reduced NFkB nuclear translocation, which constitutive activation, stimulated by HPV-oncoproteins, promotes cancer progression and functional studies revealed that OLE activated p21 Cip/WAF1 in a transcriptional-dependent-manner, by reducing the nuclear recruitment of NFkB on its responsive elements. Furthermore, OLE treatment counteracted epithelial-to-mesenchymal-transition and inhibited anchorage-dependent and -independent cell growth EGF-induced. Finally, MTT assay results revealed that OLE plus Cisplatin strengthened the reduction of cells viability Cisplatin-induced, as OLE inhibited NFkB, AkT and MAPK pathways, all involved in Cisplatin chemoresistance. In conclusion, we demonstrated that in HeLa cells OLE exerts pro-apoptotic effects, elucidating the molecular mechanism and that OLE could mitigate Cisplatin chemoresistance. Further studies are needed to explore the potential coadiuvant use of OLE for cervical cancer treatment.

Published
2019
Full Text
View/download PDF

45. Testosterone in renal transplant patients: effect on body composition and clinical parameters.

Author

Lofaro D, Perri A, Aversa A, Aquino B, Bonofiglio M, La Russa A, Settino MG, Leone F, Ilacqua A, Armentano F, Vizza D, Lupinacci S, Toteda G, and Bonofiglio R

Subjects
Adult, Aged, Biomarkers blood, Follicle Stimulating Hormone blood, Humans, Hypogonadism epidemiology, Hypogonadism genetics, Hypogonadism physiopathology, Italy epidemiology, Luteinizing Hormone blood, Middle Aged, Polymorphism, Genetic, Prevalence, Receptors, Androgen genetics, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic epidemiology, Risk Factors, Testosterone blood, Treatment Outcome, Body Composition, Hypogonadism blood, Kidney Transplantation adverse effects, Renal Insufficiency, Chronic surgery, Testosterone deficiency, Transplant Recipients
Abstract

Background: Clinical studies have demonstrated that, after renal transplantation (TX), testosterone deficiency (TD) at the time of the procedure is independently associated with lower survival of the patient and graft. However, data between TD and the functional CAG polymorphism of the androgen receptor promoter (AR) are discordant. We investigated the prevalence of TD and its association with body composition, biochemical parameters, the Aging Males' Symptoms rating scale (AMS) domains and AR polymorphism., Methods: In 112 TX patients, we assessed the AMS, biochemical/hormonal (FSH/LH/TT) anthropometric/bioimpedance analysis parameters, and AR CAG polymorphism of AR by gene sequencing., Results: Median values of total testosterone (TT) were 340 ng/dl and 52% of TX patients were affected by TD. Significant correlations between TT and FSH and FSH and LH (p = 0.005, p < 0.0001, respectively) were found. TD patients had lower estimated glomerular filtration rate (eGFR) and hemoglobin (Hb) (p = 0.034, p = 0.022 respectively) and showed higher values of C-reactive protein (p = 0.023) and fat tissue index/adipose tissue mass (p = 0.034 and p = 0.021, respectively), and lower values of serum albumin (p = 0.003) and high-density lipoprotein-cholesterol (p = 0.038) levels. Significant differences were found in the number of patients on mammalian target of rapamycin inhibitors immunosuppressant therapy (p = 0.045). Logistic regression analysis did not show any correlation between age, AMS scores, TT or CAG repeat length, gonadotropins, time of the transplant, and dialysis., Conclusions: Our results suggest that in TX recipients an appropriate sexual hormonal evaluation should be performed, as we found a high prevalence of TD. However, further studies are needed to clarify the association between TD and patient and graft survival.

Published
2018
Full Text
View/download PDF

46. Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension.

Author

Ghio S, Crimi G, Temporelli PL, Traversi E, La Rovere MT, Cannito A, Vizza D, Scelsi L, Raineri C, Guazzi M, and Oltrona Visconti L

Subjects
Dose-Response Relationship, Drug, Female, Follow-Up Studies, Heart Failure complications, Heart Failure mortality, Hemodynamics drug effects, Hemodynamics physiology, Humans, Hypertension, Pulmonary etiology, Infusions, Intravenous, Italy epidemiology, Male, Middle Aged, Retrospective Studies, Survival Rate trends, Vasodilator Agents administration & dosage, Heart Failure physiopathology, Hypertension, Pulmonary physiopathology, Nitroglycerin administration & dosage, Stroke Volume physiology, Vasodilation drug effects, Ventricular Function, Right drug effects
Abstract

Aims: The most recent European guidelines have proposed new definitions of pulmonary hypertension (PH) in left heart disease, to better approach the characteristics required to reflect the presence of pulmonary vascular disease. The purpose of this study was to assess whether different haemodynamic definitions of post-capillary PH imply a different reversibility of PH in response to acute vasodilator administration in heart failure patients with reduced ejection fraction and PH (HFrEF-PH)., Methods and Results: Right heart catheterization and reversibility testing was performed in 156 HFrEF-PH patients. Patients were classified as combined post-capillary and pre-capillary pulmonary hypertension (Cpc-PH) vs. isolated post-capillary pulmonary hypertension (Ipc-PH) and on the basis of diastolic pulmonary gradient (DPG) ≥ 7 vs. < 7 mmHg or of transpulmonary gradient (TPG) >12 vs. ≤12 mmHg. After vasodilator administration, Cpc-PH patients showed a greater per cent improvement in pulmonary vascular resistance (PVR), DPG and TPG as compared with Ipc-PH patients (all P int < 0.001); only pulmonary compliance (PCa) improved less in Cpc-PH than in Ipc-PH patients (P int = 0.007). However, despite vasodilatation, Cpc-PH patients remained in an unfavourable portion of the inverse hyperbolic relationship between PVR and PCa. The number of patients in whom PVR was reduced below 2.5 wood units was similar in Cpc-PH, DPG ≥7 mmHg and TPG >12 mmHg groups (28.3, 26.7 and 18.9%, respectively)., Conclusion: Although substantial improvements in PVR, DPG and TPG were observed in Cpc-PH patients after acute vasodilator administration, this response was associated with persistent abnormalities in the PVR vs. PCa relationship. The link between baseline right heart haemodynamics and pulmonary vascular disease remains elusive., (© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.)

Published
2018
Full Text
View/download PDF

47. An official European Respiratory Society statement: pulmonary haemodynamics during exercise.

Author

Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grünig E, Howard L, Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf A, and Olschewski H

Subjects
Advisory Committees, Cardiac Catheterization adverse effects, Echocardiography, Doppler, Europe, Humans, Hypertension, Pulmonary physiopathology, Practice Guidelines as Topic, Societies, Medical, Cardiac Output, Exercise Test, Hypertension, Pulmonary diagnosis, Vascular Resistance, Ventricular Dysfunction, Left diagnostic imaging
Abstract

There is growing recognition of the clinical importance of pulmonary haemodynamics during exercise, but several questions remain to be elucidated. The goal of this statement is to assess the scientific evidence in this field in order to provide a basis for future recommendations.Right heart catheterisation is the gold standard method to assess pulmonary haemodynamics at rest and during exercise. Exercise echocardiography and cardiopulmonary exercise testing represent non-invasive tools with evolving clinical applications. The term "exercise pulmonary hypertension" may be the most adequate to describe an abnormal pulmonary haemodynamic response characterised by an excessive pulmonary arterial pressure (PAP) increase in relation to flow during exercise. Exercise pulmonary hypertension may be defined as the presence of resting mean PAP <25 mmHg and mean PAP >30 mmHg during exercise with total pulmonary resistance >3 Wood units. Exercise pulmonary hypertension represents the haemodynamic appearance of early pulmonary vascular disease, left heart disease, lung disease or a combination of these conditions. Exercise pulmonary hypertension is associated with the presence of a modest elevation of resting mean PAP and requires clinical follow-up, particularly if risk factors for pulmonary hypertension are present. There is a lack of robust clinical evidence on targeted medical therapy for exercise pulmonary hypertension., Competing Interests: Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com, (Copyright ©ERS 2017.)

Published
2017
Full Text
View/download PDF

48. Early subclinical rejection treated with low dose i.v. steroids is not associated to graft survival impairment: 13-years' experience at a single center.

Author

Gigliotti P, Lofaro D, Leone F, Papalia T, Senatore M, Greco R, Perri A, Vizza D, Lupinacci S, Toteda G, La Russa A, De Stefano R, Romeo F, and Bonofiglio R

Subjects
Adult, Delayed Graft Function etiology, Female, Humans, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Adrenal Cortex Hormones therapeutic use, Graft Rejection drug therapy, Graft Survival, Kidney Transplantation adverse effects
Abstract

Subclinical rejection (SCR) has been variably associated with reduced graft survival, development and progression of interstitial fibrosis/tubular atrophy and chronic allograft nephropathy, but data are controversial concerning SCR treatment in terms of graft survival improvement. In this single-center retrospective study, we enrolled 174 adult kidney transplant recipients with a protocol biopsy performed at 30 days after transplantation to evaluate the incidence rate and risk factors for early SCR and its impact on 10-year graft survival. Five patients showed primary non function and were excluded. Among 159/169 (94.08 %) patients with stable graft function who underwent protocol biopsy, 17 (10.7 %) showed signs of SCR and were treated with low-dose intravenous (i.v.) steroids. Ten patients showed functional impairment, 8 (4.73 %) resulting as acute rejection. At multivariate analysis, donor age [odds ratio (OR) 1.04, 95 % confidence interval (CI) 1.01-1.09], and delayed graft function (DGF) (OR 1.08, 95 % CI 1.03-1.12) were significantly associated with SCR. The 10-year graft survival rate in the SCR group was similar to that in the normal-findings group (76.5 vs. 74.9 % respectively; p = 0.61). At multivariate Cox regression, acute [hazard ratio (HR) 5.22, 95 % CI 1.70-16.01], but not sub-clinical, rejection was independently associated with long-term graft failure. In conclusion, early protocol biopsy is a useful and safe tool to detect early SCR which seems not to affect the long-term survival. We suggest that this could be, probably, linked to early SCR treatment with low dose i.v. steroids.

Published
2016
Full Text
View/download PDF

49. Adiponectin secreted by tubular renal cells during LPS exposure worsens the cellular inflammatory damage.

Author

Perri A, Vizza D, Lupinacci S, Toteda G, De Amicis F, Leone F, Gigliotti P, Lofaro D, La Russa A, and Bonofiglio R

Subjects
AMP-Activated Protein Kinases metabolism, Active Transport, Cell Nucleus drug effects, Adiponectin genetics, Binding Sites, Cell Line, Extracellular Signal-Regulated MAP Kinases metabolism, Humans, Inflammation Mediators metabolism, JNK Mitogen-Activated Protein Kinases metabolism, Kidney Tubules, Proximal metabolism, Kidney Tubules, Proximal pathology, Nephritis genetics, Nephritis metabolism, Nephritis pathology, Phosphorylation, Promoter Regions, Genetic, RNA Interference, Receptors, Adiponectin genetics, Receptors, Adiponectin metabolism, Signal Transduction drug effects, Time Factors, Transcription Factors genetics, Transcription Factors metabolism, Transfection, Up-Regulation, Adiponectin metabolism, Autocrine Communication drug effects, Kidney Tubules, Proximal drug effects, Lipopolysaccharides toxicity, Nephritis chemically induced
Abstract

The pathogenetic role of adiponectin (ADPN) in kidney failure is not yet elucidated, since in vitro and in vivo studies have demonstrated that ADPN exerts both anti-inflammatory and pro-inflammatory effects. Starting from our previous findings demonstrating that HK-2 cells express and secrete ADPN, in this study we investigated the autocrine role of ADPN in tubular inflammatory damage induced by lipopolysaccharide (LPS) and the underlying molecular mechanisms. Firstly, we observed that short-term exposure to LPS enhanced ADPN protein expression as well as the adiponectin receptor ADIPOR1 mRNA content together with its signaling pathway downstream, pAMPK/pERK/pJNK, whose up-regulation status was reversed when ADPN gene knockdown occurred. Interestingly, in the same experimental conditions, we observed that ADPN mediated the nuclear translocation of the transcription factors nuclear factor kappa B (NFkB) and pcFos/pcJun (activator protein 1, AP-1), both induced by the pJNK pathway and involved in tumor necrosis factor (TNF)-α transactivation. Indeed, by transient transfection assay, we observed that the LPS-induced increase of TNF-α promoter activity was abrogated in cells pretreated with the inhibitors of NFkB and AP-1. Collectively our results suggest that in HK-2 cells, ADPN produced upon LPS stimulus could worsen the inflammatory damage in an autocrine-dependent manner.

Published
2016
Full Text
View/download PDF

50. Heart failure in patients with human immunodeficiency virus: a review of the literature.

Author

Cannillo M, D'Ascenzo F, Grosso Marra W, Cerrato E, Calcagno A, Omedè P, Bonora S, Mancone M, Vizza D, DiNicolantonio JJ, Pianelli M, Barbero U, Gili S, Annone U, Raviola A, Salera D, Mistretta E, Vilardi I, Colaci C, Abbate A, Zoccai GB, Moretti C, and Gaita F

Subjects
Antiretroviral Therapy, Highly Active adverse effects, HIV Infections drug therapy, HIV Infections virology, Heart Failure diagnosis, Heart Failure epidemiology, Humans, Incidence, Mass Screening methods, Prognosis, Risk Factors, Viral Load, HIV Infections complications, Heart Failure etiology
Abstract

Coronary artery disease represents the leading cause of death for HIV patients treated with highly active antiretroviral treatment. Besides this, an extensive amount of data related to the risk of overt heart failure and consequently of atrial fibrillation and sudden cardiac death (SCD) in this population has been reported. It seems that persistent deregulation of immunity in HIV-infected patients is a common pathway related to both of these adverse clinical outcomes. Despite the fact that atrial fibrillation and heart failure are relatively common in HIV, few data are reported about screening, diagnosis, and potential treatment of these conditions.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results